MANILA, Philippines – A panel of vaccine experts in the Philippines are studying the possibility of mixing various brands of COVID-19 vaccines amid issues in global vaccine supply, the Department of Science and Technology (DOST) said Tuesday.
Dr. Nina Gloriani, head of the DOST Vaccine Experts Panel (VEP), said they are considering the matter of mixing vaccine brands due to the current scarcity of vaccine supply in the Philippines.
“That is a very practical or realistic scenario that we may be looking at with these so many vaccines that we have now,” she said during a Department of Health (DOH) press briefing.
“Di ba kulang ang ating mga COVID-19 supplies? Sometimes we have to be realistic, ano yung next na pwedeng ibigay? Hindi puwedeng i-delay too long yung second dose,” she added.
Gloriani said these COVID-19 vaccines are not comparable since they are made using different technologies but she noted that some vaccines make use of the same platforms.
“There are some of them na medyo pareho ang platform like Pfizer is messenger RNA, Moderna is messenger RNA,” she said.
“For the adeno(virusDNA approach), iyong mga vector-based vaccines so iyon ang medyo marami, sila Astrazeneca… Dadating na rin ang Gamaleya (Institute) Sputnik V,” she added, referring to the vaccine developed by a Russian company.
Gloriani said a recommendation on the matter will be released soon but she stressed that guidelines for such move should be in place.
The DOH earlier said that there is still no sufficient evidence supporting the benefits of mixing COVID-19 vaccine brands.
The agency also said that it will maintain its position that whatever brand used in the first dose should also be the same brand for the second dose.